3 completed, 2 not yet recruiting, 1 unknown, 1 withdrawn. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Not yet recruiting 2, Unknown 1, Withdrawn 1 |
Follow Gastric Neoplasms: new trials by email Literature Review of Gastric Neoplasms trials Research Report on Gastric Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study Ferrous succinate, Ferrous Sulfate, Serplulimab - Gastric Neoplasms | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 54 | 2026-09-01 | 2026-10-14 |
| Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor Trastuzumab Rezetecan - Solid Tumors, Neoplasms (Cancer / Tumors) | Phase 2 | Not yet recruiting | Haihua Yuan | 15 | 2026-06-15 | 2026-06-08 |
| Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes, Olympus Graphics Interchange Format (GIF) 190 endoscope, Gastric mucosal biopsy - Gastric Cancer, Gastric Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 195 | 2023-06-22 | 2025-01-17 |
| Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Camrelizumab, Pyrotinib, Capecitabine - Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Unknown | Fudan University | 65 | 2021-12-31 | 2021-11-08 |
| Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) - Gastric Neoplasms | Phase 2 | Withdrawn | University Hospital Tuebingen | 2019-11-01 | 2025-04-03 | |
| Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome Endoscope+Cellvizio(R) 100 microscope - Gastric Cancer, Gastric Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2019-02-11 | 2021-07-12 |
| A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 ASLAN001 - Stomach Neoplasms, Cancer of Stomach | Phase 2 | Completed | ASLAN Pharmaceuticals | 24 | 2012-03-01 | 2015-01-14 |
Stomach Neoplasms (7) · Disease (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Uterine Cervical Neoplasms (1)
Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Gastrointestinal Neoplasms (7) · Neoplasms by Site (7) · Stomach Diseases (7) · Neoplasms (6) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Biliary Tract Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Endocrine Gland Neoplasms (1)
Oxaliplatin (2) · Capecitabine (1) · Paclitaxel (1) · S 1 (combination) (1) · Tegafur (1) · camrelizumab (1) · ferrous succinate (1) · ferrous sulfate (1) · pyrotinib (1)
National Cancer Institute (NCI) (2) · ASLAN Pharmaceuticals (1) · Fudan University (1) · Haihua Yuan (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University Hospital Tuebingen (1)
China (2) · United States (2) · Germany (1) · South Korea (1)
Andrew Blakely, M.D. (1) · Jeremy L Davis, M.D. (1) · Seock-Ah Im, Dr. (1)